SCHEMBL16615501

SCHEMBL16615501

CCCC(C)C(=O)Nc1ccc(S(=O)(=O)N(CCC)CCC)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 7/20 0.67
CA2 P00918 4/20 0.67
CA7 P43166 2/20 0.67
CA14 Q9ULX7 2/20 0.67
CA12 O43570 8/20 0.57
CA9 Q16790 8/20 0.57
ABCC9 O60706 1/20 0.56
ABCC8 Q09428 1/20 0.56
KCNJ11 Q14654 1/20 0.56
KCNJ8 Q15842 1/20 0.56
HSD17B10 Q99714 1/20 0.56
POLB P06746 2/20 0.54
MAPT P10636 2/20 0.54
GAA P10253 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
MEN1 O00255 1/20 0.53
ESR1 P03372 1/20 0.53
KMT2A Q03164 1/20 0.53
CTDSP1 Q9GZU7 1/20 0.53
KDM4E B2RXH2 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8222629 0.81 CA1 (1.00) CA1CA2CA7CA14CA12
SCHEMBL4189849 0.80 CA9 (0.68) CA1CA2CA12CA9ABCC9
SCHEMBL16615503 0.78 CA12 (0.61) CA1CA2CA12CA9ABCC9
SCHEMBL10119209 0.76 MAPT (0.67) CA1CA2CA12CA9ABCC9
SCHEMBL7702751 0.75 HSD17B10 (0.69) CA1CA2CA7CA14HSD17B10
SCHEMBL10169748 0.75 CA1 (0.69) CA1CA2CA7CA14ABCC9
SCHEMBL17947763 0.75 CA9 (0.90) CA1CA2CA12CA9POLB
SCHEMBL11037156 0.74 HSD17B10 (0.68) CA1CA2CA7CA14HSD17B10
SCHEMBL26783407 0.74 HSD17B10 (0.68) CA1CA2CA7CA14HSD17B10
SCHEMBL6312180 0.74 ABCC9 (0.62) CA1CA2CA7CA14CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160213679-A1 INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF Université de Montréal (CA) 2016-07-28 US disclosed
US-20160213679-A1 INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF Université de Montréal (CA) 2016-07-28 US disclosed
WO-2015042685-A1 INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF VALORISATION-RECHERCHE (CA) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160213679-A1 INHIBITORS OF POLYNUCLEOTIDE REPEAT-ASSOCIATED RNA FOCI AND USES THEREOF FBL, HNRNPA1, HNRNPUL1 CA1 4853/4885CA2 4721/4885CA7 4771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.